ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 576,93
-0,73%
Dow Jones
40 211,72
0,00%
DAX
18 497,42
-0,55%
Brent Oil
83,015
-1,57%
Bitcoin
63 958,27
-1,38%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
08/09/202222h01GlobeNewswire Inc.Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022NASDAQ:NTLAIntellia Therapeutics Inc
01/09/202222h55Dow Jones NewsIntellia Therapeutics' NTLA-2002 Genome Candidate Receives FDA's Orphan Drug DesignationNASDAQ:NTLAIntellia Therapeutics Inc
01/09/202222h01GlobeNewswire Inc.Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
26/08/202214h16TipRanksBMO Capital Remains a Hold on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
23/08/202215h59GlobeNewswire Inc.Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin SymposiumNASDAQ:NTLAIntellia Therapeutics Inc
09/08/202206h11TipRanksWhich 3 ARK Innovation Stocks Can Bounce the Most?NASDAQ:NTLAIntellia Therapeutics Inc
08/08/202218h00TipRanksAnalysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Crispr Therapeutics AG (CRSP)NASDAQ:NTLAIntellia Therapeutics Inc
05/08/202214h35TipRanksIntellia Therapeutics (NTLA) Receives a Hold from BMO CapitalNASDAQ:NTLAIntellia Therapeutics Inc
05/08/202206h53TipRanksAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Bicycle Therapeutics (BCYC) and OrthoPediatrics (KIDS)NASDAQ:NTLAIntellia Therapeutics Inc
05/08/202205h38TipRanksRobert W. Baird Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
05/08/202200h45TipRanksIntellia Therapeutics (NTLA) Gets a Buy Rating from Chardan CapitalNASDAQ:NTLAIntellia Therapeutics Inc
04/08/202222h07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NTLAIntellia Therapeutics Inc
04/08/202213h47Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
04/08/202213h30GlobeNewswire Inc.Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
27/07/202213h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
27/07/202211h08TipRanksSVB Securities Remains a Buy on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
27/06/202216h35TipRanksIntellia Therapeutics (NTLA) Receives a Buy from William BlairNASDAQ:NTLAIntellia Therapeutics Inc
27/06/202215h16TipRanksIntellia Therapeutics (NTLA) Gets a Hold Rating from BMO CapitalNASDAQ:NTLAIntellia Therapeutics Inc
26/06/202212h05TipRanksIntellia Therapeutics (NTLA) Gets a Buy Rating from Brookline Capital MarketsNASDAQ:NTLAIntellia Therapeutics Inc
24/06/202217h40TipRanksChardan Capital Thinks Intellia Therapeutics’ Stock is Going to RecoverNASDAQ:NTLAIntellia Therapeutics Inc
24/06/202213h31PR Newswire (US)Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single DoseNASDAQ:NTLAIntellia Therapeutics Inc
23/06/202218h45TipRanksJMP Securities Thinks Intellia Therapeutics’ Stock is Going to RecoverNASDAQ:NTLAIntellia Therapeutics Inc
22/06/202215h25TipRanksAnalysts Offer Insights on Healthcare Companies: Centene (CNC), Ionis Pharmaceuticals (IONS) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
17/06/202200h46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
13/06/202205h56TipRanksEvercore ISI Thinks Intellia Therapeutics’ Stock is Going to RecoverNASDAQ:NTLAIntellia Therapeutics Inc
08/06/202213h30GlobeNewswire Inc.Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022NASDAQ:NTLAIntellia Therapeutics Inc
10/05/202214h26TipRanksInvesting in These 3 Healthcare Stocks Could Double Your Money, Says Credit SuisseNASDAQ:NTLAIntellia Therapeutics Inc
09/05/202213h52TipRanksBrookline Capital Markets Thinks Intellia Therapeutics’ Stock is Going to RecoverNASDAQ:NTLAIntellia Therapeutics Inc
09/05/202208h23TipRanks3 Analyst’s Top Stocks with Huge Upside PotentialNASDAQ:NTLAIntellia Therapeutics Inc
08/05/202217h11TipRanksIntellia Therapeutics (NTLA) Receives a Buy from SVB SecuritiesNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées

BIT
P22SO0
NLBNPIT22SO0 20241220 800
BIT
P21RR7
NLBNPIT21RR7 20991231 23...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés